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Abstract
Background: Metastatic melanoma is a highly chemotherapy resistant tumour. The use of newer
targeted therapies alone and in combination with chemotherapy may offer new hope of improving
response to treatment. Dasatinib, a multi-target kinase inhibitor, is currently approved for the
treatment of chronic myeloid leukaemia and has shown promising results in preclinical studies in a
number of solid tumours.
Methods: We examined the effects of dasatinib on proliferation, chemo-sensitivity, cell cycle
arrest, apoptosis, migration and invasion in human melanoma cell lines. Expression and activation
of Src kinase, FAK and EphA2 were also examined in the melanoma cells.
Results: Dasatinib inhibited growth of three of the five melanoma cell lines. Comparison with
sorafenib showed that in these three cell lines dasatinib inhibited growth at lower concentrations
than sorafenib. Dasatinib in combination with the chemotherapy drug temozolomide showed
greater efficacy than either drug alone. Dasatinib induced cell cycle arrest and apoptosis and
significantly inhibited cell migration and invasion of melanoma cells. Dasatinib inhibition of
proliferation was associated with reduced phosphorylation of Src kinase, while decreased
phosphorylation of FAK was implicated in dasatinib-mediated inhibition of migration and invasion
in melanoma cells.
Conclusion: Dasatinib has both anti-proliferative and anti-invasive effects in melanoma cells and
combined with chemotherapy may have clinical benefit in the treatment of malignant melanoma.
Background
Metastatic melanoma is notoriously resistant to cytotoxic
chemotherapy. Commonly used agents such as dacar-
bazine and temozolomide yield poor response rates of
less than 20% [1] and combination regimes have not been
proven superior over single agents [2]. Therefore novel,
more efficacious treatment strategies are urgently needed
for melanoma.
Sorafenib (BAY43-9006) inhibits vascular endothelial
growth factor receptor (VEGFR) and Raf kinase, but also
has activity against c-kit and platelet derived growth factor
receptor beta (PDGFR-β). Activating B-Raf mutations are
detected in greater than 60% of malignant melanomas [3]
and sorafenib inhibits the growth of melanoma cells car-
rying B-Raf mutations. Sorafenib has shown little activity
as a single agent in the treatment of malignant melanoma,
Published: 29 September 2008
Journal of Translational Medicine 2008, 6:53 doi:10.1186/1479-5876-6-53
Received: 27 August 2008
Accepted: 29 September 2008
This article is available from: http://www.translational-medicine.com/content/6/1/53
© 2008 Eustace et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Translational Medicine 2008, 6:53 http://www.translational-medicine.com/content/6/1/53
Page 2 of 11
(page number not for citation purposes)
irrespective of B-Raf status [4], however in combination
with carboplatin it has shown promising clinical activity
[5] and is presently being tested in several clinical trials in
melanoma either alone or in combination with other
agents http://www.clinicaltrials.gov.
Src kinase regulates key pathways in metastasis including
cell adhesion, invasion and motility [6] and members of
the Src family have been implicated in melanoma progres-
sion [7-11]. Both Src and Yes are reported to be elevated
in melanoma cells compared to normal melanocytes
[7,12]. Dasatinib, a multi-target tyrosine kinase inhibitor,
targets Src kinase, in addition to BCR-Abl, c-KIT, PDGFR
and ephrin-A receptor kinases. It is the most potent Src
kinase inhibitor currently in clinical development with an
IC50 of 0.5 nM for Src kinase (IC50 of < 30 nM for the other
targets) [13]. Dasatinib has shown preclinical activity in
prostate cancer [14], triple negative breast cancer [15] and
colon cancer cells.
Due to the deficiency of effective treatment options for
advanced melanoma and the reported relationship
between Src kinase and melanoma progression, we exam-
ined the preclinical activity of Src inhibition, using dasat-
inib, alone and in combination with temozolomide in
metastatic melanoma cell lines.
Methods
Cells and reagents
Lox-IMVI, Malme-3M, Sk-Mel-5, and Sk-Mel-28 were
obtained from the Department of Developmental Thera-
peutics, National Cancer Institute (NCI) and HT144 from
the American Tissue Culture Centre (ATCC). Cell lines
were grown at 37°C with 5% CO2 in RPMI medium with
10% FCS (Gibco) except HT144 which was grown in
McCoys 5A (Sigma-Aldrich) with 10% FCS. Stock solu-
tions of temozolomide (9.7 mM), (Department of Devel-
opmental Therapeutics, National Cancer Institute),
epirubicin (3.45 mM), taxotere (11.6 μM) (Dept of Phar-
macy, St. Vincent's University Hospital), dasatinib (10
mM), sorafenib (10 mM) (Sequoia Research Products)
and imatinib (16.9 mM) (Novartis) were prepared in
dimethyl sulfoxide (Sigma-Aldrich).
Preparation of cell extracts for Western blotting
500 μL RIPA buffer with 1 × protease inhibitors, 2 mM
PMSF and 1 mM sodium orthovanadate (Sigma-Aldrich)
was added to cells and incubated on ice for 20 minutes.
Following centrifugation at 10,000 rpm for 5 minutes at
4°C the resulting lysate was stored at -80°C. Protein
quantification was performed using the Bicinchoninic
acid (BCA) assay (Pierce). 40 μg of protein in sample
buffer was heated to 95°C for 5 minutes and proteins
were separated on 7.5 or 10% gels (Cambrex). The protein
was transferred to Hybond-ECL nitrocellulose membrane
(Amersham Biosciences). The membrane was blocked
with blocking solution (PBS + 0.1% Tween + 5%
skimmed milk powder (BioRad)) at room temperature for
1 hour, then incubated overnight at 4°C with 1 μg/ml pri-
mary antibody (mouse anti-Epha2, Millipore; mouse
anti-Src kinase, Upstate Cell Signalling Solutions; rabbit
anti-phospho-Src py 418, Biosource Europe; mouse anti-
FAK kinase BD Biosciences; rabbit anti-FAK py 861 and py
397, Invitrogen; mouse anti-tubulin, Sigma-Aldrich) in
blocking solution. The membrane was washed three times
with PBS-Tween, then incubated at room temperature
with anti-mouse secondary antibody (Sigma-Aldrich) at
1:1000 dilution or anti-rabbit secondary antibody
(Pierce) at 1:3000 dilution) in blocking solution for 1
hour. The membrane was washed three times with PBS-
Tween followed by one PBS wash. Detection was per-
formed using Luminol (Santa Cruz Biotechnology). For
detection of phosphorylated EphA2, EphA2 was immuno-
precipitated from 500 μg of protein using EphA2 antibody
(Millipore) and immunoblotted with a mouse anti-phos-
photyrosine antibody (Upstate Cell Signalling Solutions).
Proliferation assay
Proliferation was measured using an acid phosphatase
assay. 1 × 103 cells/well were seeded in 96-well plates,
apart from HT144 and Malme-3M which were seeded at 2
× 103 cells/well. Plates were incubated overnight at 37°C
followed by addition of drug at the appropriate concen-
trations and incubated for a further 5 days until wells were
80% to 90% confluent. All media was removed and the
wells were washed once with PBS. Paranitrophenol phos-
phate substrate (0.263 g of PNP in 100 ml sodium acetate
buffer) was added to each well and incubated at 37°C for
2 hours. 50 μl of 1 M NaOH was added and the absorb-
ance was read at 405 nM (reference – 620 nM), as previ-
ously described [16].
Invasion assays
Invasion and migration assays were performed as previ-
ously described [17], using 1 × 105 cells in matrigel-coated
24-well invasion inserts for invasion assays and uncoated
inserts for migration assays. Cells were incubated for 6
hours before dasatinib treatment to allow cells to attach
and then incubated at 37°C with dasatinib at varying con-
centrations for 24 hours. Cells were stained with crystal
violet and the number of invading/migrating cells was
estimated by counting 10 fields of view at 200 × magnifi-
cation. The average count was multiplied by the conver-
sion factor 140 (growth area of membrane divided by
field of view area, viewed at 200 × magnification) to deter-
mine the total number of invading/migrating cells. All
assays were performed in triplicate.Journal of Translational Medicine 2008, 6:53 http://www.translational-medicine.com/content/6/1/53
Page 3 of 11
(page number not for citation purposes)
Terminal DNA transferase-mediated dUTP nick end 
labelling (TUNEL) assay
2.5 × 104 cells were seeded per well in 24-well plates and
incubated overnight at 37°C, followed by addition of
drug at the appropriate concentrations. After 72 hours,
media was collected and the wells washed once with PBS.
Cells were trypsinised and added to the media collected
for each sample. Cells were centrifuged at 300 × g for 5
minutes and the media was aspirated. 150 μl of PBS was
added, the pellet re-suspended and the total volume trans-
ferred to a round bottomed 96 well plate. 50 μL of 4%
para-formaldehyde was added to the wells and mixed.
Cells were incubated at 4°C for 60 minutes. The plate was
centrifuged at 300 × g for 5 minutes and the supernatant
aspirated leaving approximately 15 μL in each well. The
remaining volume was used to resuspend the cells and
200 μL of ice cold 70% ethanol was added to the cells. The
plates were then stored at -20°C for 2 hours. After fixing
the cells were stained according to the protocol for the
TUNEL assay (Guava Technologies). Cells were analysed
on the Guava EasyCyte (Guava Technologies). Positive
and negative controls were performed with each assay.
Cell cycle assays
2.5 × 104 cells were seeded per well in 24-well plates and
incubated overnight at 37°C. After 24 hours cells were
synchronised by removing the media and replacing it with
serum free medium (SFM) for a further 24 hours. SFM was
removed and the cells incubated for a further 6 hours in
media containing serum before the drug was added at the
appropriate concentrations. Plates were then incubated at
37°C for a further 24 hours. Media was collected and the
wells washed once with PBS. Cells were trypsinised and
added to the media collected for each sample. Cells were
centrifuged at 300 × g for 5 minutes and the media was
aspirated. 150 μl of PBS was added, the pellet re-sus-
pended and the total volume transferred to a round bot-
tomed 96 well plate. The plate was centrifuged at 300 × g
for 5 minutes and the supernatant aspirated leaving
approximately 15 μL in each well. The remaining volume
was used to resuspend the cells and 200 μL of ice cold
70% ethanol was added. The plates were then stored at -
20°C for 2 hours. After fixing the cells were stained
according to the protocol for the Guava Cell Cycle assay
(Guava Technologies). Cells were analysed on the Guava
EasyCyte and the data was analysed using Modfit LT soft-
ware (Verity).
Statistical analysis
IC50 values were calculated using CalcuSyn software (Bio-
Soft). For Lox-IMVI, combination index (CI) values were
calculated using CalcuSyn software. A CI value of < 1 is
considered synergistic, 1 is considered additive and > 1 is
considered antagonistic. CI values were not calculated for
the other cell lines, as dasatinib did not achieve 50% inhi-
bition of growth at concentrations up to 1 μM. The Stu-
dent's t  test was used to compare temozolomide IC50s
alone and in combination with dasatinib, migration/inva-
sion assays and cell cycle assays P < 0.05 was considered
statistically significant. ANOVA one way analysis was per-
formed to compare dasatinib alone, taxotere/epirubicin
alone and the combination. P < 0.05 was considered sta-
tistically significant.
Results
Sensitivity to dasatinib
The effect of dasatinib on proliferation was tested in a
panel of five melanoma cell lines (Figure 1). Lox-IMVI dis-
plays the greatest sensitivity to dasatinib with an IC50 of
35.4 nM (± 8.8 nM). HT144 and Malme-3M also display
some sensitivity to dasatinib with a maximum growth
inhibition of 40% and 30%, respectively, achieved in
these cell lines at 1 μM dasatinib. Growth of Sk-Mel-28
and Sk-Mel-5 appear to be slightly increased in response
to dasatinib treatment. IC50 values for sorafenib ranged
from the most sensitive cell line Sk-Mel-5 (IC50 = 1.4 ± 0.4
μM) to the most resistant HT144 (IC50 = 4.1 ± 0.4 μM).
Sensitivity to the multi-target kinase inhibitor, imatinib,
was also examined in HT144 and Lox-IMVI cells. Imatinib
did not inhibit the growth of either cell line at concentra-
tions up to 5 μM (See additional file 1: Effect of imatinib
on proliferation).
Dasatinib in combination with chemotherapy
The effect of dasatinib in combination with chemother-
apy was examined in the three dasatinib responsive cell
lines, Lox-IMVI, HT144 and Malme-3M and in one of the
dasatinib-resistant cell lines, Sk-Mel-28. In both HT144
and Malme-3M, dasatinib enhanced response to temo-
zolomide (Figure 2). In Lox-IMVI, CI values (CI value at
ED50 = 0.88 ± 0.03) revealed the combination of dasatinib
and temozolomide was slightly synergistic. The IC50 for
temozolomide when administered in combination with
dasatinib, was significantly reduced compared to temo-
zolomide alone in HT144 (227 μM versus 359 μM, p =
0.038) and in Malme-3M (212 μM versus 343 μM, p =
0.024). In Sk-Mel-28, which is resistant to dasatinib,
temozolomide combined with dasatinib produces a simi-
lar response to temozolomide alone (See Additional file
2: Temozolomide IC50s).
The effects of dasatinib in combination with epirubicin
and taxotere were also examined in HT144 and Lox-IMVI
(See additional file 3: Combination assays of dasatinib
with epirubicin or taxotere). In both HT144 and Lox-
IMVI, dasatinib combined with epirubicin increased inhi-
bition of proliferation compared to either drug alone. The
combination of taxotere and dasatinib also significantly
increased inhibition of proliferation compared to either
drug alone.Journal of Translational Medicine 2008, 6:53 http://www.translational-medicine.com/content/6/1/53
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Percentage growth inhibition by A) dasatinib and B) sorafenib in a panel of melanoma cell lines Figure 1
Percentage growth inhibition by A) dasatinib and B) sorafenib in a panel of melanoma cell lines. Error bars rep-
resent the standard deviation of triplicate experiments.
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Combination assays testing dasatinib with temozolomide at the specified ratios in (A) HT144 (ratio 1:1500), (B) Lox-IMVI  (ratio 1:3000), (C) Malme-3M (ratio 1:800) and (D) Sk-Mel-28 (ratio 1:800) cells Figure 2
Combination assays testing dasatinib with temozolomide at the specified ratios in (A) HT144 (ratio 1:1500), 
(B) Lox-IMVI (ratio 1:3000), (C) Malme-3M (ratio 1:800) and (D) Sk-Mel-28 (ratio 1:800) cells. Concentrations of 
temozolomide are represented as a ratio of the dasatinib concentration. Error bars represent the standard deviation of tripli-
cate experiments.
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Effect of dasatinib on apoptosis and cell cycle arrest
In Lox-IMVI and Malme-3M cells, increasing concentra-
tions of dasatinib induced apoptosis (Figure 3). However,
in HT144 cells dasatinib does not appear to induce apop-
tosis with concentrations up to 200 nM. Dasatinib treat-
ment resulted in a slight increase in G1 arrest in HT144 (p
= 0.07) and a significant increase in Lox-IMVI (p =
0.0045), compared to control untreated cells (Table 1).
Dasatinib did not induce cell cycle arrest in Sk-Mel-28 or
Malme-3M cells (See additional file 4: Effect of dasatinib
on cell cycle arrest).
Effect of dasatinib on invasion and migration
The effects of dasatinib on invasion and migration were
examined in two invasive cell lines, one dasatinib sensi-
tive (HT144) and one resistant cell line (Sk-Mel-28).
Dasatinib significantly decreased invasion of HT144 and
Sk-Mel-28 cells (25 nM dasatinib: HT144 p = 0.05; Sk-
Mel-28 p = 0.016) (Figure 4A) and migration of both cell
lines (25 nM dasatinib: HT144 p = 0.001; Sk-Mel-28 p =
0.019) (Figure 4B). The concentrations of dasatinib used
in the invasion/migration assays were non-toxic to the
cells (data not shown).
Effect of dasatinib on Src kinase, EphA2 and FAK
Src, EphA2, FAK and phosphorylated Src, EphA2 and FAK
were detected in all cell lines tested, although the levels of
phosphorylated Src kinase detected were low (Figure 5A).
Phosphorylation of Src was decreased in HT144, Lox-
IMVI and Malme-3M in response to dasatinib treatment
(Figure 5B), but the level of Src phosphorylation appeared
to be slightly increased in Sk-Mel-28 cells treated with
dasatinib (Figure 5B). EphA2 phosphorylation was
unchanged in all cell lines tested, after 6 hours of treat-
ment with 100 nM dasatinib. In Lox-IMVI cells treated
with 100 nM dasatinib for up to 48 hours, EphA2 phos-
phorylation was transiently reduced after 30 minutes but
activation was restored by 2 hours. Phospho-FAK py861
was reduced in all cell lines tested after treatment with
dasatinib whereas phospho-FAK py397 was unaffected by
treatment with dasatinib.
Discussion
We have evaluated the effects of dasatinib, a multi-tar-
geted tyrosine kinase inhibitor, in human melanoma cell
lines [6]. In a previous study in breast cancer cell lines,
sensitivity to dasatinib was characterised as greater than
60% inhibition, moderate sensitivity as 40–59% inhibi-
tion and resistance as less than 40% inhibition in
response to 1 μM dasatinib [15] (assuming higher concen-
trations would not be achievable in vivo) [15]. Therefore,
Lox-IMVI can be classified as being highly sensitive to
dasatinib, HT144 moderately sensitive and the remaining
three cell lines are resistant, although Malme-3M shows
some sensitivity.
Measurement of dasatinib induced apoptosis in HT144, Lox-IMVI and Malme-3M using the TUNEL assay Figure 3
Measurement of dasatinib induced apoptosis in HT144, Lox-IMVI and Malme-3M using the TUNEL assay.
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Sorafenib which is currently in clinical trials for advanced
melanoma, has shown little activity when tested alone but
shows promising results when tested in combination with
chemotherapy [5]. In the five cell lines tested in this study,
which are B-Raf mutated http://www.sanger.ac.uk/genet
ics/CGP/cosmic/, the IC50 for sorafenib was above 1 μM in
each case. These results suggest that dasatinib-sensitive
melanoma cells are more sensitive to dasatinib than to
sorafenib in vitro.
Furthermore, dasatinib in combination with temozolo-
mide significantly improved response in HT144 and Lox-
IMVI compared to either drug alone. In Malme-3M cells,
there was a small but significant improvement in response
compared to temozolomide alone. In the dasatinib-resist-
ant cell line Sk-Mel-28, the combination was slightly bet-
ter than temozolomide alone although the difference was
not significant. Therefore the combination of dasatinib
with temozolomide may improve response in some
melanoma patients. In dasatinib resistant tumours, the
addition of dasatinib would not impact on sensitivity to
temozolomide but may help to prevent further tumour
spread by inhibiting melanoma cell migration and inva-
sion, as we observed in dasatinib-resistant Sk-Mel-28 cells.
Studies in lung cancer [18], head and neck squamous cell
carcinoma [19] and malignant pleural mesothelioma [20]
showed that dasatinib induces both cell cycle arrest and
apoptosis. In Lox-IMVI, the most sensitive cell line, treat-
ment with dasatinib induced both apoptosis and cell cycle
arrest. In the other dasatinib responsive cell lines, HT144
and Malme-3M, dasatinib induced either cell cycle arrest
or apoptosis respectively. Therefore, optimal response to
dasatinib in melanoma cells may require efficient induc-
tion of both cell cycle arrest and apoptosis.
Imatinib targets Bcr-Abl, c-Kit and PDGFR. Previous stud-
ies identified that c-kit expression was reduced with
melanoma progression and trials testing imatinib as a sin-
gle agent showed no benefit in the clinical setting [21,22].
However recent studies have identified a group of chronic
sun damaged patients who maintain c-kit expression
despite melanoma progression [23] and as a result clinical
trials have been undertaken to target c-kit with imatinib in
this population [21].
Imatinib however does not inhibit the growth of either
HT144 or Lox-IMVI cells. Thus sensitivity of melanoma
cell lines to dasatinib may be due to targeting Src kinase
or EphA receptors, which are not targeted by imatinib.
Differences in the level or phosphorylation of Src kinase
do not appear to predict sensitivity to dasatinib in the
melanoma panel. Similar to preclinical studies in other
solid tumour types [20], phosphorylation of Src was
reduced in dasatinib sensitive cell lines, whereas in the
dasatinib resistant cell lines Sk-Mel-28 and Sk-Mel-5,
phospho-Src was either unchanged or slightly increased,
in response to dasatinib treatment. Thus inhibition of Src
phosphorylation may be an appropriate marker of
response to dasatinib. Serrels et al [24] showed that inhi-
bition of phospho-Src in peripheral blood mononuclear
cells correlated with inhibition of phospho-Src in colon
tumours. Measuring changes in phospho-Src in peripheral
blood mononuclear cells may therefore serve as a surro-
gate marker for response to dasatinib in the clinic [25].
Previous studies have shown that dasatinib treatment did
not reduce phosphorylation of FAK at Tyr397, an auto-
phosphorylation site required for recruitment of Src
kinase which in turn phosphorylates FAK at Tyr576,
Tyr577, and Tyr861 [24]. Phosphorylation at these sites is
important for FAK downstream signalling [26]. Dasatinib
reduced the level of FAK phosphorylation at Tyr861 in all
of the melanoma cell lines and therefore does not appear
to be associated with inhibition of proliferation but may
play a role in inhibition of migration and invasion in
melanoma cells. In colon cancer cells, reduced phosphor-
ylation of FAK at tyrosine 861 was implicated in dasat-
inib-mediated inhibition of migration and invasion [24].
Recently enzyme assays have shown that dasatinib is a
potent inhibitor of several additional kinases, including
FAK (IC50  = 0.2 nM) [27]. Therefore, dasatinib may
Table 1: Percentage of cells in the G1 phase of the cell cycle, in control and dasatinib treated samples.
Cell Lines Control 50 nM Dasatinib 100 nM Dasatinib 200 nM Dasatinib
HT144 51.6
± 4.5
58.3
± 1.2
59.6
± 2.1
59.4
± 6.1
Lox-IMVI 35.4
± 3.0
51.0 *
± 4.6
56.6 *
± 4.6
53.0 *
± 6.6
Malme-3M 71.7
± 1.5
70.2
± 4.0
70.9
± 2.0
69.5
± 2.4
Sk-Mel-5 57.6
± 1.6
55.3
± 2.2
57.6
± 3.3
58.9
± 4.3
Note: '*' indicates p < 0.05.Journal of Translational Medicine 2008, 6:53 http://www.translational-medicine.com/content/6/1/53
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Effect of dasatinib on (A) invasion and (B) migration in HT144 and Sk-Mel-28 melanoma cell lines Figure 4
Effect of dasatinib on (A) invasion and (B) migration in HT144 and Sk-Mel-28 melanoma cell lines. Error bars 
represent the standard deviation of triplicate assays. '*' indicates p < 0.05.
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Western blotting for Src kinase, phospho-Src kinase py 418, FAK, phospho-FAK py 397 and py 861, immunoprecipitated (IP)  EphA2, IP phospho-EphA2 and α-tubulin in (A) the panel of melanoma cell lines; and (B) HT144, Lox-IMVI, Malme-3M, Sk-Mel- 5 and Sk-Mel-28 untreated (control) or treated with 100 nM dasatinib for 6 hours Figure 5
Western blotting for Src kinase, phospho-Src kinase py 418, FAK, phospho-FAK py 397 and py 861, immuno-
precipitated (IP) EphA2, IP phospho-EphA2 and α-tubulin in (A) the panel of melanoma cell lines; and (B) 
HT144, Lox-IMVI, Malme-3M, Sk-Mel-5 and Sk-Mel-28 untreated (control) or treated with 100 nM dasatinib 
for 6 hours. (C) Western blotting for IP EphA2, IP phospho-EphA2 in Lox-IMVI untreated (control) and treated with 100 nM 
dasatinib for up to 48 hours.
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directly target FAK, independently of Src, resulting in inhi-
bition of migration/invasion without inhibition of prolif-
eration, as was observed in Sk-Mel-28 cells.
Other dasatinib preclinical studies did not examine the
role of EphA receptors in response to dasatinib. EphA2
has been identified as a potential dasatinib sensitivity
biomarker [28]. Interestingly EphA2 levels were signifi-
cantly higher in the three dasatinib sensitive cell lines than
in the two resistant cell lines. Although the number of cell
lines is small, this suggests that EphA2 expression may
predict response to dasatinib treatment and warrants fur-
ther investigation in a larger panel of cell lines. Dasatinib
treatment for 6 hours had no effect on phosphorylation of
EphA2. However, in Lox-IMVI, phosphorylation of EphA2
was transiently decreased at 30 minutes, but was restored
by 2 hours. EphA2 activity may also be altered by
decreased phosphorylation of Src and FAK, which form a
complex with EphA2 [29]. Dasatinib may also target other
members of the Ephrin receptor family such as EphB4
[27]. Further research is required to elucidate the role of
Ephrin receptors in response to dasatinib treatment in
melanoma and other solid tumours.
The in vitro effects of dasatinib in melanoma cell lines
observed in this study provide strong evidence for evalua-
tion of dasatinib in clinical trials in melanoma patients.
Two clinical trials of dasatinib in melanoma are currently
underway, including a phase I/II study of dasatinib in
combination with dacarbazine http://www.clinicaltri
als.gov.
Conclusion
Our preclinical evaluation of dasatinib, shows that it has
anti-proliferative, pro-apoptotic and anti-invasive effects
in some melanoma cells in vitro. Furthermore, combining
dasatinib with temozolomide improved response in
melanoma cell lines. Thus, dasatinib is an exciting new
therapeutic option for malignant melanoma. Phospho-
Src represents a promising pharmacodynamic marker for
response to dasatinib and high levels of EphA2 may be a
predictive marker for dasatinib. Identification and valida-
tion of appropriate biomarkers will be crucial to maximise
the potential clinical benefits of dasatinib treatment for
melanoma.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AJE contributed to the design of the study and carried out
the proliferation assays, TUNEL assays, cell cycle assays,
Western blotting and statistical analysis. JC and MC con-
tributed to the interpretation of the data. NOD conceived
the study, supervised the research, and participated in
interpretation of the data and drafting the manuscript. All
authors read and approved the final manuscript.
Additional material
Acknowledgements
We would like to acknowledge funding from the Programme for Research 
in Third Level Institutes (PRTLI) from the Higher Education Authority of 
Ireland and the Targeted Research Initiative Fund, Faculty of Science and 
Health, Dublin City University.
References
1. Gogas HJ, Kirkwood JM, Sondak VK: Chemotherapy for meta-
static melanoma: time for a change?  Cancer 2007,
109(3):455-464.
2. Quirt I, Verma S, Petrella T, Bak K, Charette M: Temozolomide for
the treatment of metastatic melanoma: a systematic review.
Oncologist 2007, 12(9):1114-1123.
3. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD,
Robertson GP: Mutant V599EB-Raf regulates growth and vas-
cular development of malignant melanoma tumors.  Cancer
Res 2005, 65(6):2412-2421.
4. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I,
Hackett S, James M, Schuchter LM, et al.: Sorafenib in advanced
melanoma: a Phase II randomised discontinuation trial anal-
ysis.  Br J Cancer 2006, 95(5):581-586.
5. Flaherty KT: Sorafenib: delivering a targeted drug to the right
targets.  Expert Rev Anticancer Ther 2007, 7(5):617-626.
Additional file 1
Effect of imatinib on proliferation. The data compares the effect of imat-
inib on the proliferation of HT144 and Lox-IMVI.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-
5876-6-53-S1.doc]
Additional file 2
Comparison of IC50 concentrations of temozolomide when tested alone 
and in combination with dasatinib in HT144, Lox-IMVI, Malme-3M and 
Sk-Mel-28 cells. Standard deviations represent average results of triplicate 
experiments. IC50 values were compared using the Student's T-test.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-
5876-6-53-S2.doc]
Additional file 3
Combination assays of dasatinib with epirubicin or taxotere in HT144 
and Lox-IMVI.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-
5876-6-53-S3.doc]
Additional file 4
Effect of dasatinib on cell cycle arrest. 
Effect of dasatinib on cell cycle arrest. Comparing the effect of dasatinib 
versus untreated cells on the percentage of cells tested in the G1, S and 
G2/M phases of cell cycle.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1479-
5876-6-53-S4.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Translational Medicine 2008, 6:53 http://www.translational-medicine.com/content/6/1/53
Page 11 of 11
(page number not for citation purposes)
6. Homsi J, Cubitt C, Daud A: The Src signaling pathway: a poten-
tial target in melanoma and other malignancies.  Expert Opin
Ther Targets 2007, 11(1):91-100.
7. Barnekow A, Paul E, Schartl M: Expression of the c-src protoon-
cogene in human skin tumors.  Cancer Res 1987, 47(1):235-240.
8. Marchetti D, Parikh N, Sudol M, Gallick GE: Stimulation of the
protein tyrosine kinase c-Yes but not c-Src by neurotrophins
in human brain-metastatic melanoma cells.  Oncogene 1998,
16(25):3253-3260.
9. Huang J, Asawa T, Takato T, Sakai R: Cooperative roles of Fyn and
cortactin in cell migration of metastatic murine melanoma.
J Biol Chem 2003, 278(48):48367-48376.
10. Qi J, Wang J, Romanyuk O, Siu CH: Involvement of Src family
kinases in N-cadherin phosphorylation and beta-catenin dis-
sociation during transendothelial migration of melanoma
cells.  Mol Biol Cell 2006, 17(3):1261-1272.
11. Wellbrock C, Weisser C, Geissinger E, Troppmair J, Schartl M: Acti-
vation of p59(Fyn) leads to melanocyte dedifferentiation by
influencing MKP-1-regulated mitogen-activated protein
kinase signaling.  J Biol Chem 2002, 277(8):6443-6454.
12. Loganzo F Jr, Dosik JS, Zhao Y, Vidal MJ, Nanus DM, Sudol M, Albino
AP: Elevated expression of protein tyrosine kinase c-Yes, but
not c-Src, in human malignant melanoma.  Oncogene 1993,
8(10):2637-2644.
13. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Cas-
taneda S, Cornelius LA, Das J, Doweyko AM, et al.: Discovery of N-
(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piper-
azin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxa-
mide (BMS-354825), a dual Src/Abl kinase inhibitor with
potent antitumor activity in preclinical assays.  J Med Chem
2004, 47(27):6658-6661.
14. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J,
Lee FY, Jove R: Action of the Src family kinase inhibitor, dasat-
inib (BMS-354825), on human prostate cancer cells.  Cancer
Res 2005, 65(20):9185-9189.
15. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N,
Slamon DJ: Dasatinib, an orally active small molecule inhibitor
of both the src and abl kinases, selectively inhibits growth of
basal-type/"triple-negative" breast cancer cell lines growing
in vitro.  Breast Cancer Res Treat 2007, 105(3):319-326.
16. Martin A, Clynes M: Acid phosphatase: endpoint for in vitro
toxicity tests.  In Vitro Cell Dev Biol 1991, 27A(3 Pt 1):183-184.
17. Glynn SA, Gammell P, Heenan M, O'Connor R, Liang Y, Keenan J,
Clynes M: A new superinvasive in vitro phenotype induced by
selection of human breast carcinoma cells with the chemo-
therapeutic drugs paclitaxel and doxorubicin.  Br J Cancer 2004,
91(10):1800-1807.
18. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB: Dasatinib
(BMS-354825) selectively induces apoptosis in lung cancer
cells dependent on epidermal growth factor receptor signal-
ing for survival.  Cancer Res 2006, 66(11):5542-5548.
19. Johnson FM, Saigal B, Talpaz M, Donato NJ: Dasatinib (BMS-
354825) tyrosine kinase inhibitor suppresses invasion and
induces cell cycle arrest and apoptosis of head and neck
squamous cell carcinoma and non-small cell lung cancer
cells.  Clin Cancer Res 2005, 11(19 Pt 1):6924-6932.
20. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG,
Hong WK, Wistuba I, Johnson FM: Inhibition of c-Src expression
and activation in malignant pleural mesothelioma tissues
leads to apoptosis, cell cycle arrest, and decreased migration
and invasion.  Mol Cancer Ther 2007, 6(7):1962-1972.
21. Becker JC, Brocker EB, Schadendorf D, Ugurel S: Imatinib in
melanoma: a selective treatment option based on KIT muta-
tion status?  J Clin Oncol 2007, 25(7):e9.
22. Ugurel S, Hildenbrand R, Zimpfer A, La Rosee P, Paschka P, Sucker A,
Keikavoussi P, Becker JC, Rittgen W, Hochhaus A, et al.: Lack of
clinical efficacy of imatinib in metastatic melanoma.  Br J Can-
cer 2005, 92(8):1398-1405.
23. Curtin JA, Busam K, Pinkel D, Bastian BC: Somatic activation of
KIT in distinct subtypes of melanoma.  J Clin Oncol 2006,
24(26):4340-4346.
24. Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ,
Ashton GH, Frame MC, Brunton VG: Identification of potential
biomarkers for measuring inhibition of Src kinase activity in
colon cancer cells following treatment with dasatinib.  Mol
Cancer Ther 2006, 5(12):3014-3022.
25. Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML,
Smykla R, Fager K, Wild R, Palme H, et al.: Identification and vali-
dation of phospho-SRC, a novel and potential pharmacody-
namic biomarker for dasatinib (SPRYCELtrade mark), a
multi-targeted kinase inhibitor.  Cancer Chemother Pharmacol
2008.
26. Parsons JT: Focal adhesion kinase: the first ten years.  J Cell Sci
2003, 116(Pt 8):1409-1416.
27. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson
S, Mathieson T, Perrin J, Raida M, Rau C, et al.: Quantitative chem-
ical proteomics reveals mechanisms of action of clinical ABL
kinase inhibitors.  Nat Biotechnol 2007, 25(9):1035-1044.
28. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, Lee F,
Shaw P, Clark E: Identification of candidate molecular markers
predicting sensitivity in solid tumors to dasatinib: rationale
for patient selection.  Cancer Res 2007, 67(5):2226-2238.
29. Parri M, Buricchi F, Giannoni E, Grimaldi G, Mello T, Raugei G, Ram-
poni G, Chiarugi P: EphrinA1 activates a Src/focal adhesion
kinase-mediated motility response leading to rho-dependent
actino/myosin contractility.  J Biol Chem 2007,
282(27):19619-19628.